News

Local Doctor Discusses Novavax Vaccine, Georgia’s Response To Combating Pandemic

Dr. Harry Heiman discusses the new two-shot COVID-19 vaccine made by Novavax.
Dr. Harry Heiman discusses the new two-shot COVID-19 vaccine made by Novavax.
Credit Courtesy photo

Dr. Harry Heiman, a clinical associate professor in the Division of Health Management and Policy at the School of Public Health at Georgia State University, says given the response from the U.S. and the state of Georgia at the start of the pandemic, it’s incredible to see the progress that has been made in vaccine creation and vaccination rates.

“I think the other thing that’s important for people to realize when they see both national and state numbers is there are tremendous differences both across the country and within states, and there are profound disparities and inequities that need to be looked at,” said Heiman on Thursday’s edition of “Closer Look.”

Heiman talked with show host Rose Scott about coronavirus-related topics, including the effectiveness of the new two-shot COVID-19 vaccine made by Novavax and why the new vaccine may not be the key to getting more people vaccinated.

The fact of the matter is, the rate-limiting step in the U.S. is not vaccine supply,” said Heiman. “It’s putting resources in place to do outreach to those communities with the greatest needs and communities who to date aren’t being vaccinated at the same rates as others.”

To listen to the full conversation, click the audio player above.